Apollo and Blackstone Complete $35 Billion Anthropic AI Infrastructure Financing Deal 
Alaska Air Group Eyes Return of Financial Guidance as Fuel Market Volatility Eases 
Naver Stock Jumps on NVIDIA Partnership to Build South Korea’s AI Infrastructure 
J.P. Morgan Sees Major Upside for Prysmian as Optical Fiber Prices Surge 
MOL Gets More Time to Negotiate Acquisition of Russian-Owned Stake in Serbia’s NIS 
Foreign Firms Cash In on India's IPO Boom 
Airbus Aircraft Deliveries Surge in May 2026 
Lululemon Cuts 2026 Outlook as Weak North America Sales Pressure Growth 
Nvidia Expands South Korea AI Partnerships to Strengthen Data Center and Memory Chip Supply 
Apollo Ends Pursuit of Bodycote, Withdraws £1.52 Billion Takeover Proposal 
BitGo Expands Regulated Crypto Trading Services in MENA 
Netflix Names Jay Hoag as Board Chairman Following Reed Hastings’ Departure 
oOh!media Takeover Battle Intensifies as Bain Capital Joins Competing Bids 
US Officials Explore AI Company Equity Stakes Ahead of OpenAI and Anthropic IPO Plans 
South Korea Weighs AI Profit Sharing as Samsung and SK Hynix Earnings Surge 
Intesa Sanpaolo Launches €30.6 Billion Bid for Monte dei Paschi to Drive Italian Banking Consolidation 
ASIC Launches Formal Investigation Into KPMG Australia Partners Over Client Data Misuse Allegations 
Pfizer Inc. revealed that it received informal requests relating to its operations in China from the US Department of Justice and the US Securities and Exchange Commission (SEC) in June and August.
According to Pfizer, it is producing records to satisfy requests for documents from the Foreign Corrupt Practices Act units of the Justice Department and the SEC.
The 1977 Foreign Corrupt Practices Act makes it illegal for US firms and those whose stock is traded in the US to bribe foreign government officials.
In 2012, the drugmaker had to shell out $26.3 million as a settlement for illegal payments in winning overseas deals, including those in Russia, Bulgaria, China, the Middle East, and Italy.
China is a big growth market for global pharmaceutical companies. But they have to face tightened regulations, heightened tensions between China and the US, and China’s efforts to promote local generic drugmakers.
